Resources & Guides

The definitive guide to retatrutide (reta) pharmacokinetics: approximately 6 days half-life per NEJM Phase 2 data, 30-day full clearance, and 4-5 week steady state per dose level. Includes half-life comparison to tirzepatide and semaglutide, dosing implications, and FAQ.

Split dosing semaglutide twice weekly takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. Every semaglutide product is FDA-approved for once-weekly dosing only, so this is off-label. Here is the pharmacokinetic reasoning, the pen-mechanics problem, and what has never been tested.

Technical overview of the pharmacokinetic model behind GLP3Planner. Covers the one-compartment model with first-order absorption, the Bateman equation, drug parameters sourced from clinical trials, multi-dose superposition and steady state, the reconstitution math (BAC water to syringe units), and the standard per-compound titration ladders.

Everything you need to know about semaglutide (Ozempic/Wegovy): GLP-1 mechanism, FDA-approved dosing protocols, half-life pharmacokinetics, side effects, and our free calculator to track your journey.

A twice-weekly retatrutide split takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. The 6-day half-life is what makes that spacing logical. Here is the pharmacokinetic reasoning, the practical mechanics, and the honest evidence picture.

Dive deep into pharmacokinetic principles, from basic half-life concepts to complex compartmental models, and understand how individual factors affect drug concentrations.